MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases
Hepatocellular carcinomas (HCCs) are aggressive tumors with a poor prognosis. Approved first-line treatments include sorafenib, lenvatinib, and a combination of atezolizumab and bevacizumab; however, they do not cure HCC. We investigated MBP-11901 as a drug candidate for HCC. Cell proliferation and...
Main Authors: | Hyun Jin Park, Garam Choi, Seongmin Ha, Yesl Kim, Min-Jin Choi, Minsup Kim, Md. Kamrul Islam, Yongmin Chang, Tae-Jun Kwon, Dongkyu Kim, Eunbee Jang, Tae Hwan Kim, Sha Joung Chang, Yeoun-Hee Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/8/1994 |
Similar Items
-
Synthesis, Characterization, and Anticancer Activity of Benzothiazole Aniline Derivatives and Their Platinum (II) Complexes as New Chemotherapy Agents
by: Md. Kamrul Islam, et al.
Published: (2021-08-01) -
Nonsteroidal Anti-Inflammatory Drug Conjugated with Gadolinium (III) Complex as an Anti-Inflammatory MRI Agent
by: Bokyung Sung, et al.
Published: (2023-04-01) -
The Synthesis, Characterization, Molecular Docking and In Vitro Antitumor Activity of Benzothiazole Aniline (BTA) Conjugated Metal-Salen Complexes as Non-Platinum Chemotherapeutic Agents
by: Md. Kamrul Islam, et al.
Published: (2022-06-01) -
Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling
by: Ji Hoon Phi, et al.
Published: (2015-10-01) -
Development of a Biotechnology Platform for the Fast-Growing Cyanobacterium <em>Synechococcus</em> sp. PCC 11901
by: Lauren A. Mills, et al.
Published: (2022-06-01)